Bio

Carmichael is a founding partner of Material Impact, a fund that seeks out transformative technologies and builds them into enduring companies that solve real-world problems. The fund's strategy is based on Carmichael’s successful career as an entrepreneur-investor in “materials,” blending a unique business model of licensing university technology and commercializing it through targeted partnerships with Fortune 500 companies. Carmichael is also a member of Breakthrough Energy, a mission-oriented group committed to changing the world by creating and building companies that address the threat of climate change and long-term sustainability of the planet. As part of their work, Breakthrough Energy will invest over $1B over the next 20 years to help scale products for energy, transportation, agriculture, and construction. As a General Partner at North Bridge Venture Partners, Carmichael financed and built several successful companies, including 1366 technologies and Foro Energy. As co-founder and chairman of nonprofit Diagnostics For All, he is developing paper-based diagnostics to serve marginalized patients globally. Prior to North Bridge, Carmichael co-founded several ventures, and served as President and CEO of Arsenal Medical. Prior to his entrepreneurial career, he worked in BD at GelTex Pharmaceuticals, acquired by Genzyme for $1.3 billion, and in new product and business development at Dow Chemical. Carmichael serves on the boards for the National Venture Capital Association and Massachusetts General Hospital Physician Organization. In 1999, he was named by MIT’s Technology Review as one of the world’s top 100 young entrepreneurs. Carmichael is a trustee of Duke University. Carmichael received his BS and PhD in organic chemistry from Duke University and completed his postdoctoral National Science Foundation fellowship at Harvard University. Carmichael also has an MBA from MIT Sloan School of Management.